Hereditary Colorectal Cancer Registries in Canada: Report from the Colorectal Cancer Association of Canada Consensus Meeting; Montreal, Quebec; October 28, 2011

Rothenmund, Heidi; Singh, Harminder; Candas, Bernard; Chodirker, B. N.; Serfas, Kim; Aronson, Melyssa; Holter, Spring; Volenik, Alexandra; Green, J.; Dicks, Elizabeth; Woods, Michael O.; Gilchrist, Dawna; Gryfe, Robert; Cohen, Zane; Foulkes, William D.

doi:10.3747/co.20.1566

Cited by 5 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain lncRNAs, such as H19 , MALAT , and linc-POU3F3 , have been shown to be involved in cancer progression, and also glioma of different malignancy grades show different patterns of lncRNA expression [ 22 – 24 ]. Also, expression of miRNAs shows biomarker potential, used as diagnostic support or for prognostic and therapeutic application [ 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Identifying Novel Glioma-Associated Noncoding RNAs by Their Expression Profiles

Matjašič

Tajnik

Boštjančič

et al. 2017

International Journal of Genomics

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) play a significant role in cancer development as regulators of protein-coding genes. Their dysregulation was in some extent already associated with glioma, the most aggressive primary brain tumours in adults. The correct diagnosis and treatment selection due to high tumour heterogeneity might be difficult and inadequate, resulting in poor prognosis. Studies of expression patterns of noncoding RNAs (ncRNAs) could provide useful insight in glioma molecular development. We used the qPCR approach to screen and investigate the expression of lncRNAs that were previously deregulated in other cancer types. The study showed altered expression levels for numerous lncRNAs across histologically different glioma samples. Validation of few lncRNAs showed association of expression levels with histological subtype and/or malignancy grade. We also observed deregulated and subtype-distinctive expression for four lncRNA-associated miRNAs. Expression of few lncRNAs and miRNA was also associated with patients' survival, showing potential prognostic value. Several ncRNAs, some already related to glioma and some, to the best of our knowledge, investigated for the first time, might be of greater importance in glioma molecular development and progression. Finding the subtype-specific lncRNA and/or miRNA expression patterns may contribute additional information for a more objective classification.

show abstract

Section: Introductionmentioning

confidence: 99%

Identifying Novel Glioma-Associated Noncoding RNAs by Their Expression Profiles

Matjašič

Tajnik

Boštjančič

et al. 2017

International Journal of Genomics

View full text Add to dashboard Cite

show abstract

“…Organized patient navigation and provision of screening/surgery is highly variable in Canada, and patients consistently report difficulties in co-ordination of recommended care. Large-scale implementation of germline testing will require parallel development of hereditary cancer registries [ 49 , 50 , 51 , 52 ]. Registries can be run at low cost but deliver high value as they ensure high-risk individuals access effective prevention, evidence-based care, patient support, and access to research.…”

Section: Results Of Panel Discussionmentioning

confidence: 99%

Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention

et al. 2022

View full text Add to dashboard Cite

Individuals with proven hereditary cancer syndrome (HCS) such as BRCA1 and BRCA2 have elevated rates of ovarian, breast, and other cancers. If these high-risk people can be identified before a cancer is diagnosed, risk-reducing interventions are highly effective and can be lifesaving. Despite this evidence, the vast majority of Canadians with HCS are unaware of their risk. In response to this unmet opportunity for prevention, the British Columbia Gynecologic Cancer Initiative convened a research summit “Gynecologic Cancer Prevention: Thinking Big, Thinking Differently” in Vancouver, Canada on 26 November 2021. The aim of the conference was to explore how hereditary cancer prevention via population-based genetic testing could decrease morbidity and mortality from gynecologic cancer. The summit invited local, national, and international experts to (1) discuss how genetic testing could be more broadly implemented in a Canadian system, (2) identify key research priorities in this topic and (3) outline the core essential elements required for such a program to be successful. This report summarizes the findings from this research summit, describes the current state of hereditary genetic programs in Canada, and outlines incremental steps that can be taken to improve prevention for high-risk Canadians now while developing an organized population-based hereditary cancer strategy.

show abstract

“…The World Health Organization recommends that all genetics centers establish registries of genetically determined disease [40]. Canadian recommendations similarly support the implementation of hereditary cancer registries, noting they will 1) improve the identification of high risk individuals; 2) improve their access to appropriate clinical and genetic screening; and 3) improve survival rates for at-risk carrier relatives [41]. Genetic registries of this nature are used in other jurisdictions and have improved patient outcomes [11,17,[41][42][43][44][45][46][47].…”

Section: Possible Solutions: Inherited Cancer Registries Patient Navi...mentioning

confidence: 99%

“…A Canadian consensus group reviewed the evidence on registries and summarized their positive clinical outcomes, largely derived from increased enrolment of at-risk individuals who subsequently undergo appropriate cancer screening; high rates of surveillance compliance were observed, with noncompliance rates of less than 5% [ 41 ]. Registries have demonstrated a decline in the incidence of cancer [ 47 ] and improved survival rates, not only for known carriers, but for their relatives identified as carriers who subsequently undergo targeted screening [ 17 , 41 , 47 ]. While much of the work of Canadian registries has been carried out in research settings, findings have been translated to clinical care to the benefit of patients and families [ 41 ].…”

Section: Introductionmentioning

confidence: 99%

“…Registries have demonstrated a decline in the incidence of cancer [ 47 ] and improved survival rates, not only for known carriers, but for their relatives identified as carriers who subsequently undergo targeted screening [ 17 , 41 , 47 ]. While much of the work of Canadian registries has been carried out in research settings, findings have been translated to clinical care to the benefit of patients and families [ 41 ]. Long standing research registries in Finland similarly show improved screening and survival in LS families over three generations [ 48 ], although high numbers of at risk, untested individuals remain, even in these well-established cohorts.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer prevention in cancer predisposition syndromes: A protocol for testing the feasibility of building a hereditary cancer research registry and nurse navigator follow up model

et al. 2022

View full text Add to dashboard Cite

Monogenic, high penetrance syndromes, conferring an increased risk of malignancies in multiple organs, are important contributors to the hereditary burden of cancer. Early detection and risk reduction strategies in patients with a cancer predisposition syndrome can save their lives. However, despite evidence supporting the benefits of early detection and risk reduction strategies, most Canadian jurisdictions have not implemented programmatic follow up of these patients. In our study site in the province of Newfoundland and Labrador (NL), Canada, there is no centralized, provincial registry of high-risk individuals. There is no continuity or coordination of care providing cancer genetics expertise and no process to ensure that patients are referred to the appropriate specialists or risk management interventions. This paper describes a study protocol to test the feasibility of obtaining and analyzing patient risk management data, specifically patients affected by hereditary breast ovarian cancer syndrome (HBOC; BRCA 1 and BRCA 2 genes) and Lynch syndrome (LS; MLH1, MSH2, MSH6, and PMS2 genes). Through a retrospective cohort study, we will describe these patients’ adherence to risk management guidelines and test its relationship to health outcomes, including cancer incidence and stage. Through a qualitative interviews, we will determine the priorities and preferences of patients with any inherited cancer mutation for a follow up navigation model of risk management. Study data will inform a subsequent funding application focused on creating and evaluating a research registry and follow up nurse navigation model. It is not currently known what proportion of cancer mutation carriers are receiving care according to guidelines. Data collected in this study will provide clinical uptake and health outcome information so gaps in care can be identified. Data will also provide patient preference information to inform ongoing and planned research with cancer mutation carriers.

show abstract

Hereditary Colorectal Cancer Registries in Canada: Report from the Colorectal Cancer Association of Canada Consensus Meeting; Montreal, Quebec; October 28, 2011

Cited by 5 publications

References 35 publications

Identifying Novel Glioma-Associated Noncoding RNAs by Their Expression Profiles

Identifying Novel Glioma-Associated Noncoding RNAs by Their Expression Profiles

Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention

Cancer prevention in cancer predisposition syndromes: A protocol for testing the feasibility of building a hereditary cancer research registry and nurse navigator follow up model

Contact Info

Product

Resources

About